💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Aimmune's AR101 successful in late-stage peanut allergy study; shares up 6% premarket

Published 03/05/2018, 07:39 AM
© Reuters.  Aimmune's AR101 successful in late-stage peanut allergy study; shares up 6% premarket
AIMT
-
  • Aimmune Therapeutics (NASDAQ:AIMT) is up 6% premarket on light volume on the heels of its announcement of successful results from the Phase 3 PALISADE study of AR101 in people with peanut allergy. The data were presented at the American Academy of Allergy, Asthma & Immunology-World Allergy Organization Joint Congress in Orlando, FL.
  • The results were previously reported last month. Treatment with AR101 produced a statistically significant desensitization to peanut protein at month 12.
  • The company expects to file its U.S. marketing application by year-end followed by an application in Europe in H1 2019.
  • Previously: Aimmune's lead candidate successful in late-stage peanut allergy study; shares ahead 19% premarket (Feb. 20)
  • Now read: Aimmune Therapeutics: Insider Buying Alert


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.